ReviewFrontiers in pharmacology2018
Non-nucleotide Agonists Triggering P2X7 Receptor Activation and Pore Formation.
Review in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 85 citations in OpenAlex.
- Effects on mouse melanoma and immune cells of P2X7 receptor positive allosterism by clemastine.Purinergic signalling · 2026Article
- P2X7 receptor: An emerging therapeutic target in acute myeloid leukemia (Review).International journal of oncology · 2026Review
- Participation of the purinergic P2X7 receptor in molecular complexes in the nucleus of human chondrocytes.Cellular and molecular life sciences : CMLS · 2026Article
- Effects of New P2X7R Antagonists on Retinal Inflammatory Degenerative Conditions.Inflammation · 2026Article
- The P2X7 Receptor and Its Relation to Neglected Tropical Diseases: Focusing on Chagas Disease.Journal of tropical medicine · 2026Review
- P2X7 blockade inhibits the growth of breast cancer in 4T1 breast cancer-bearing mice by NLRP3/caspase 1 pathway.Archives of medical science : AMS · 2026Article
- P2X7 Receptor in Rare Diseases: Shared Molecular Mechanisms and Therapeutic Implications.Journal of inflammation research · 2026Review
- Lessons from the physiological role of guanosine in neurodegeneration and cancer: Toward a multimodal mechanism of action?Purinergic signalling · 2025Review
- Article
- Purinergic Receptor (P2X7R): A Promising Anti-Parkinson's Drug Target.Advanced pharmaceutical bulletin · 2024Review
- Ionotropic purinergic receptor 7 (P2X7) channel structure and pharmacology provides insight regarding non-nucleotide agonism.Channels (Austin, Tex.) · 2024Review
- P2X7 receptors and pannexin1 hemichannels shape presynaptic transmission.Purinergic signalling · 2024Review
- P2X7 receptor knockout does not alter renal function or prevent angiotensin II-induced kidney injury in F344 rats.Scientific reports · 2024Article
- P2X7 Receptor in Dendritic Cells and Macrophages: Implications in Antigen Presentation and T Lymphocyte Activation.International journal of molecular sciences · 2024Review
- P2X7 Receptor-Induced Human Mast Cell Degranulation Is Enhanced by Interleukin 33.International journal of molecular sciences · 2024Article
- Design, synthesis and mechanistic anticancer activity of new acetylated 5-aminosalicylate-thiazolinone hybrid derivatives.iScience · 2024Article
- The P2X7 Receptor in Autoimmunity.International journal of molecular sciences · 2023Review
- Purinergic signaling via P2X receptors and mechanisms of unregulated ATP release in the outer retina and age-related macular degeneration.Frontiers in neuroscience · 2023Review
- cGAMP the travelling messenger.Frontiers in immunology · 2023Review
- The shed P2X7 receptor is an index of adverse clinical outcome in COVID-19 patients.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The P2X7 receptor (P2X7R) is a ligand-gated plasma membrane ion channel belonging to the P2X receptor subfamily activated by extracellular nucleotides. General consensus holds that the physiological (and maybe the only) agonist is ATP. However, scattered evidence generated over the last several years suggests that ATP might not be the only agonist, especially at inflammatory sites. Solid data show that NAD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.